The first Hemp and CBD Congress in Southern Europe took place on Friday, April 27. A pioneering professional meeting in Spain focused on the analysis and projection of this emerging and rapidly expanding industry.
With 165 participants , 26 speakers and more than a hundred companies represented from Europe (Spain, France, Austria, Luxembourg, Germany, Italy, Belgium, Switzerland, Greece, the Netherlands, the United Kingdom, the Czech Republic and Croatia), North America (Canada, the United States) and South America (Chile, Peru and Colombia), the first edition of HBD has been a very positive event, both in terms of the relevance of the presentations and the number of professionals attending.
Beemine Laboratories attended as professionals, and the most important and outstanding was the thematic block in which the Regulation and legal status of cannabinoids was discussed. From 1:30 p.m. to 2:45 p.m. the debate focused on the Spanish context and the market opportunities that can be opened from the Autonomous Communities. Under the coordination of the lawyer and director of S&F, Bernardo Soriano , the legal keys were offered about the position of the WHO regarding CBD as an ingredient that could be included in the catalogs of the so-called "Novel Food" products. Miguel Torres , from Baker Tilly Abogados, shared a table with Tomas Sadilek , Director of Government Affairs of the International Cannabis and Cannabinoids Institute (ICCI) and with the French activist Kenzi Riboulet-Zemouli .
In this section, topics of interest were discussed, such as the regulatory change in March 2018, where cannabis sativa L extracts were no longer considered a food supplement in the "list of authorized food supplements" of the Spanish Agency for Medicines and Health Products (AEMPS).
Only the extracts from the stem or seeds are approved for marketing as food or food supplement.
We must remember that CBD is an unaudited product, meaning it is not illegal, but effective immediately, nor is it legal to use as a food supplement. Thus, until CBD is listed, it is illegal to sell it for human consumption and is therefore prohibited until its regulation is shaped.
